Abstracts Archive - Page 45 of 2425 - ACR Meeting Abstracts

Abstract Number: 0582 • ACR Convergence 2024
Achievement of Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Chao Song², Nicole Middaugh³, Maya Marchese³, Melissa Eliot³, Robert Low² and Philip Mease⁴, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UCB Pharma, Smyrna, GA, ³CorEvitas, LLC, Waltham, MA, ⁴Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Minimal disease activity (MDA) is associated with clinically meaningful improvements in disease activity and patient (pt)-reported outcomes among pts with PsA.1 However, it is…
Abstract Number: 0525 • ACR Convergence 2024
Assess the Effect of Increasing the Dose of Folic Acid Supplementation in Patients of Rheumatoid Arthritis with Methotrexate Intolerance – A Randomised Controlled Trial
Varun Dhir¹, Harshith Sai Koneti², Aman Sharma³, sanjay jain⁴ and shankar naidu⁵, ¹PGIMER, CHD, INDIA, CHANDIGARH, India, ²PGIMER, Chandigarh, Sangareddy, Telangana, India, ³PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, ⁴PGIMER, Chandigarh, Chandigarh, India, ⁵PGIMER, Chandigarh, India, Chandigarh, India
Background/Purpose: : Methotrexate (MTX) Intolerance continues to occur in 20-40% patients despite low-dose folic acid (5-10mg per week) supplementation. Would a higher dose of folic…
Abstract Number: 0517 • ACR Convergence 2024
Characterizing Infusion-Related Reactions in Patients with Rheumatoid Arthritis Treated with Biologic DMARDs: Observations from the KOBIO Registry
Ji-Won Kim¹, Ju-Yang Jung², Chang-Hee Suh³ and Hyoun-Ah Kim¹, ¹Ajou university school of medicine, Suwon, South Korea, ²Ajou University of medical school, Suwon, South Korea, ³Ajou University Hospital, Suwon, South Korea
Background/Purpose: The use of biologic disease-modifying antirheumatic drugs (bDMARDs) has revolutionized the management of rheumatoid arthritis (RA), despite their efficacy being occasionally limited by infusion-related…
Abstract Number: 0554 • ACR Convergence 2024
Different Prevalence of Intestinal Inflammation in Radiographic and Non-radiographic Axial Spondyloarthritis. Data from EISER Study
Carolina Merino¹, Zulema Plaza², Jordi Gratacos Masmitja³, Iago Rodríguez-Lago⁴, Elisa Trujillo⁵, Ignacio Marin-Jimenez⁶, Eva Perez Pampin⁷, Manuel Barreiro⁸, Vanesa Hernández-Hernández⁹, Marta Carrillo-Palau¹⁰, Maria Luz Garcia Vivar¹¹, Maria Carmen Muñoz¹², María Lourdes Ladehesa-Pineda¹³, Eva Iglesias Flores¹⁴, Yago González-Lama¹⁵, Marta Arevalo Salaet¹⁶, Xabier Calvet¹⁷, Ana Gutierrez-Casbas¹⁸ and JESUS SANZ SANZ¹⁹, and EISER group, ¹Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, ²Fundacion Española de Reumatología, Madrid, Spain, ³University Hospital Parc Taulí, Sabadell, Spain, ⁴Gastroenterology department. Hospital Universitario Galdakao-Usansolo, Instituto de Investigación Sanitaria Biobizkaia, Galdakao, Bizkaia, Spain, Galdakao, Spain, ⁵Rheumatology department. Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, ⁶Gastroenterology department. Hospital Universitario Gregorio Marañón, Madrid, Spain, ⁷Rheumatology department. Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Santiago de Compostela, Spain, ⁸Gastroenterology department. Hospital Clínico Universitario de Santiago de Compostela Santiago de Compostela, Spain, Santiago de Compostela, Spain, ⁹Hospital Universitario de Canarias, San Cristobal de La Laguna, Canarias, Spain, ¹⁰Gastroenterology department. Hospital Universitario Canarias, La Laguna, Spain., Santa Cruz de Tenerife, Spain, ¹¹Basurto Hospital, Bilbao, Spain, ¹²Gastroenterology department. Hospital Universitario Basurto Hospital Universitario Basurto. Bilbao. Spain., Bilbao., Spain, ¹³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ¹⁴Gastroenterology department. Hospital Reina Sofia, Córdoba, Spain, Cordoba, Spain, ¹⁵Servicio de Gastroenterología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Majadahonda, Spain, ¹⁶Parc Tauli Hospital Universitari I3PT, Rheumatology, Medicine Department, UAB, Sabadell, Spain, ¹⁷Gastroenterology department. Parc Taulí, Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí. Universitat Autònoma de Barcelona. Sabadell, Spain, Sabadell, Spain, ¹⁸Gastroenterology department. Hospital General Universitario de Dr. Balmis de Alicante. ISABIAL y CIBERehd, Alicante, Spain, Alicante, Spain, ¹⁹Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain
Background/Purpose: Axial spondyloarthritis (AxSpA) encompasses both non-radiographic axial spondyloarthritis (nr-AxSpA) and radiographic axial spondyloarthritis (r-AxSpA), also known as ankylosing spondylitis (AS). Although nr-AxSpA is often…
Abstract Number: 0570 • ACR Convergence 2024
Prevalence of Comorbidities and Racial Disparities in Anterior Uveitis Risk Among Ankylosing Spondylitis Patients
Halah Alfatlawi¹, abdulmajeed alharbi², eun seo kwak², rawnag el sheikh² and nezam altorok², ¹the university of toledo, Toledo, OH, ²the university of toledo, Toledo
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the axial spine, commonly associated with extra-articular manifestations such as anterior uveitis (AU). Racial…
Abstract Number: 0620 • ACR Convergence 2024
Clinical Efficacy and Patient-Reported Outcomes in Anti-Ro/Sjögren’s Syndrome–Related Antigen a Antibody–Positive Patients with Active SLE Treated WithDeucravacitinib in the Phase 2 PAISLEY Trial
Benjamin A. Fisher¹, Hendrika Bootsma², Vibeke Strand³, Wan-Fai Ng⁴, Thomas Wegman⁵, Brandon Becker⁶, Jiyoon Choi⁶, Antoine Sreih⁶, Leo Chen⁷, Antonia Christodoulou⁶ and Eric Morand⁸, ¹University of Birmingham, Birmingham, United Kingdom, ²Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, ³Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁴Institute of Cellular Medicine, Newcastle University, Gateshead, United Kingdom, ⁵Bristol Myers Squibb, Beaver Falls, PA, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Richmond, BC, Canada, ⁸School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of adults with moderate to…
Abstract Number: 0607 • ACR Convergence 2024
Plasma Proteomic Analysis Reveals Type I Interferon Blockade Effects of Anifrolumab in Lupus Nephritis: Insights from a Phase 2 Trial
Andrea Fava¹, Michelle Petri², David Jayne³, Patrick G Gavin⁴, Eszter Csomor⁵, Philip Z Brohawn⁴, Daniel Muthas⁶, Adam Platt⁵, Catharina Lindholm⁷ and Nicola Ferrari⁵, ¹Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³University of Cambridge, Cambridge, United Kingdom, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁷BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
Background/Purpose: An elevated type I interferon gene signature (IFNGS) is associated with more active disease in patients with LN.1 Anifrolumab, a type I interferon receptor…
Abstract Number: 0638 • ACR Convergence 2024
Soluble TNF RII in Lupus Nephritis as a Biomarker of Disease Activity and Treatment Response
Ranjan Gupta¹, Sonam Rajput², Jayanth Kumar² and Dipendra K Mitra², ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²All India Institute of Medical Sciences, New Delhi, New Delhi, India
Background/Purpose: Lupus Nephritis (LN) affects almost 60-70% patients of Systemic Lupus Erythematosus (SLE). Conventional markers of renal involvement i.e. proteinuria and renal biopsy have limitations…
Abstract Number: 0651 • ACR Convergence 2024
Renal Survival and Mortality in Patients with Proliferative and Membranous Lupus Nephritis
Jung-Min Shin¹, Jiyoung Lee², Hye-Soon Lee³, Sang-Cheol Bae³ and So-Young Bang³, ¹Department of Rheumatology, Nowon Eulji Medical Center, Seoul, Republic of Korea, ²Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Lupus nephritis (LN) affects approximately 50% of patients and is a major determinant in the survival and prognosis of patients with systemic lupus erythematosus…
Abstract Number: 0564 • ACR Convergence 2024
The Risk of Venous Thromboembolism in Axial Spondyloarthritis: A Population-based Study
Mayas Arraf¹, Devy Zisman², walid Saliba³, Nili Stein⁴ and Joy Feld⁵, ¹Technion medical school, Haifa, Israel, ²Carmel Medical Center, Haifa, Israel, ³Carmel medical center, Haifa, Israel, ⁴Department of Community Medicine and Epidemiology, Haifa, Israel, ⁵Carmel and Zvulun Medical Centre, Haifa, Israel
Background/Purpose: Scarce data exist regarding the incidence of venous thromboembolism events (VTE); pulmonary embolism (PE) and deep vein thrombosis (DVT), in patients with axial spondylarthritis…
Abstract Number: 0622 • ACR Convergence 2024
Translation, Adaptation and Validation of the Brazilian-Portuguese Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) Version: Partial Results from a Single Centre
Clarice Mata Machado, Cristina Lanna, Juliana Garrido, Fabiana Moura and Rosa Telles, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Background/Purpose: In recent years, several indices of disease activity in SLE have been proposed. The Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) showed a high…
Abstract Number: 0555 • ACR Convergence 2024
The Effect of Alcohol Consumption on Clinical Outcomes and Structural Damage in Patients with Axial Spondyloarthritis: A Systematic Literature Review and Meta-Analysis
Sinead Maguire¹, Nigil Haroon², Robert Inman³, Melanie Anderson⁴, Evelyne Gendron⁵ and Sindhu R. Johnson⁶, ¹University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Rheumatology, Toronto, Canada, ²Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴The Institute for Education Research, Library and Information Services, University Health Network, Toronto, ON, Canada, ⁵University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Rheumatology, Quebec City, QC, Canada, ⁶University of Toronto, Toronto, Canada
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic progressive inflammatory disease characterized by the involvement of the axial skeleton. Alcohol consumption (AC) is a modifiable lifestyle…
Abstract Number: 0568 • ACR Convergence 2024
Coexistence of Raynaud’s Phenomenon, Morphea or Scleroderma in Spondyloarthritis Patients: Insights from a Retrospective Cohort Study Highlighting a Unique Phenotype
Ameesh Dev, Cary Roy, Deepak Jagannath, Alexandra Cloutet and Sarah Kazzaz, Houston Methodist Hospital, Houston, TX
Background/Purpose: Spondyloarthritis (SpA) is a heterogeneous group of inflammatory arthritides that includes ankylosing spondylitis (AS), psoriatic arthritis (PsA), enteropathic-related arthritis, reactive arthritis, and undifferentiated SpA.…
Abstract Number: 0558 • ACR Convergence 2024
Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data
Maureen Dubreuil¹, Marina Magrey², Kathrin Haeffs³, Evgueni Ivanov⁴ and Julie Gandrup Horan⁵, ¹Section of Rheumatology, Boston University School of Medicine, Boston, MA, ²Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Bulle, Switzerland, ⁵UCB Pharma, Slough, United Kingdom
Background/Purpose: The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging, resulting in poor clinical, psychological, social, and economic outcomes.1 Understanding the factors…
Abstract Number: 0550 • ACR Convergence 2024
Is the Diagnostic Delay Getting Shorter with Time for Patients with Spondyloarthritis? Data from the International ASAS-PerSpA Study
Nelly Ziade¹, Ihsane Hmamouchi², Clementina López Medina³, Maroun Aoun⁴, Sherif Gamal⁵, Maxime Dougados⁶ and Bassel Elzorkany⁷, and ASAS-PerSpA, ¹Saint-Joseph University, Beirut, Lebanon, ²International University of Rabat, Rabat, Morocco, ³Reina Sofia University Hospital, Cordoba, Spain, ⁴Saint Joseph University, Beirut, Lebanon, ⁵Cairo University, Cairo, Egypt, ⁶Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁷Private (BZRC), Cairo, Egypt
Background/Purpose: Although diagnostic tools and management of spondyloarthritis (SpA) have recently improved, data on their impact on diagnostic delay (DD) are still conflicting. In this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].